Common Contracts
8 similar Placement Agency Agreement contracts by Cur Media, Inc., Enumeral Biomedical Holdings, Inc., Neurotrope, Inc., others
GP NURMENKARI INC. NORWALK, CT 06854 TEL: 212-447-5550 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 17th, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which GP Nurmenkari Inc., a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as the “Placement Agent”), shall be engaged by Neurotrope Inc., a publicly traded Nevada corporation (hereinafter referred to as the “Company”), to act as Placement Agent in connection with the registered direct offering (the “Offering”) of the securities of the Company referred to below (the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”). The Closing (as defined below) of the Offering will be conditioned upon certain conditions described herein.
KATALYST SECURITIES LLC NEW YORK, NY 10038 TEL: 212-587-6667 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 31st, 2017 • Cur Media, Inc. • Radio broadcasting stations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Katalyst Securities LLC (“Katalyst”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as the “Placement Agent”), shall be engaged by CÜR Media, Inc., a publicly traded Delaware corporation (hereinafter referred to as the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of the 12% Senior Secured Convertible Promissory Notes of the Company (the “Bridge Notes”). No minimum Offering amount is required to complete and close the Offering.
KATALYST SECURITIES LLC NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPC GP NURMENKARI INC. NORWALK, CT. 06850 TEL: 212-447-5550 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 14th, 2017 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Katalyst Securities LLC (“Katalyst”) and GP Nurmenkari Inc. (“GPN”), each a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter collectively referred to as the “Placement Agents”), shall be engaged by Enumeral Biomedical Holdings, Inc., a publicly traded Delaware corporation (hereinafter referred to as the “Company”), to act as the co-exclusive Placement Agents in connection with the private placement (the “Offering”) of the securities of the Company referred to below. The initial closing of the Offering will be conditioned upon and acceptance of subscriptions for the Minimum Amount (as defined below) and the certain other conditions described herein.
KATALYST SECURITIES LLC NEW YORK, NY 10019 TEL: 212-400-6993 Member: FINRA & SIPC GP NUREMENKARI INC. NEW YORK, NY 10017 TEL: 212-447-5550 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 18th, 2016 • Neurotrope, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Katalyst Securities LLC (“Katalyst”) and GP Nurmenkari Inc. (“GPN”), both registered broker-dealers and members of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to collectively as the “Placement Agents”), shall be engaged by Neurotrope Inc., a publicly traded Nevada corporation (hereinafter referred to as the “Company”), to act as co lead Placement Agents in connection with the private placement (the “Offering”) of the securities of the Company referred to below (the “Securities”). The First Closing (as defined below) of the Offering will be conditioned upon and acceptance of subscriptions for the Minimum Amount (as defined below) and the certain other conditions described herein. As a condition to the First Closing of the Offering, all of the outstanding shares of Series B Preferred Stock will be converted into shares of the Company’s common stock (“Common Stock”) pursuant to th
KATALYST SECURITIES LLC NEW YORK, NY 10019 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 10th, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Katalyst Securities LLC, a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as “Katalyst” or the “Placement Agent”), shall be engaged by Enumeral Biomedical Holdings, Inc., a publicly traded Delaware corporation (hereinafter referred to as the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of the 12% Senior Secured Promissory Notes of the Company (the “Bridge Notes”). The initial closing of the Offering will be conditioned upon acceptance of subscriptions for the Minimum Amount (as defined in Section 1(a) below). Capitalized terms used in this Agreement which are defined herein, shall have the meanings given to them in the Subscription Agreement and/or Bridge Note for the Offering.
KATALYST SECURITIES LLC NEW YORK, NY 10038 TEL: 212-587-6667 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 18th, 2016 • Atrinsic, Inc. • Services-business services, nec • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Katalyst Securities LLC (“Katalyst”), registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as the “Placement Agent”), shall be engaged by Atrinsic, Inc., a publicly traded Delaware Corporation (hereinafter referred to as the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of the securities of the Company (the “Securities”). The initial closing of the Offering will be conditioned upon and acceptance of subscriptions for the Minimum Amount (as defined below) and the consummation of a reverse triangular merger (the “Merger”) by and among a subsidiary of the Company, Protagenic Therapeutics Inc. (“PTI”), a privately held Delaware corporation, and the Company and certain other transactions described herein, pursuant to which PTI will become a wholly owned subsidiary of the Company, and all of
KATALYST SECURITIES LLC NEW YORK, NY 10038 TEL: 212-587-6667 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 14th, 2016 • Cur Media, Inc. • Radio broadcasting stations • New York
This Placement Agency Agreement ("Agreement") sets forth the terms upon which Katalyst Securities LLC ("Katalyst"), a registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") (hereinafter referred to as the "Placement Agent"), shall be engaged by CÜR Media, Inc., a publicly traded Delaware corporation (hereinafter referred to as the "Company"), to act as exclusive Placement Agent in connection with the private placement (the "Offering") of the 12% Senior Secured Convertible Promissory Notes of the Company (the "Bridge Notes"). The initial closing of the Offering will be conditioned upon acceptance of subscriptions for the Minimum Amount (as defined in Section 1(a) below).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 29th, 2015 • Akoustis Technologies, Inc. • Services-prepackaged software • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Northland Securities, Inc. (“Northland”) and Katalyst Securities, LLC (“Katalyst”), registered broker-dealers and members of the Financial Industry Regulatory Authority (“FINRA”), (hereinafter referred to as the “Placement Agents”), shall be engaged by Danlax Corp. (to be renamed Akoustis Technologies, Inc., a publicly traded Nevada Corporation (hereinafter referred to as the “Company”), to act as exclusive co-Placement Agents in connection with the private placement (the “Offering”) of the securities of the Company (the “Securities”). The initial closing of the Offering will be conditioned upon and acceptance of subscriptions for the Minimum Amount (as defined below) and the consummation of a reverse triangular merger (the “Merger”) by and among a subsidiary of the Company, Akoustis, Inc., (“Akoustis”), a privately held Delaware corporation, and the Company and certain other transactions describe herein, pur
